Percutaneous Radiofrequency Ablation in the Treatment of Primary Liver Cancers

Reference work entry


The development of image-guided percutaneous techniques for local tumor ablation has been one of the major advances in the treatment of liver malignancies. Among these methods, radiofrequency (RF) ablation is currently established as the primary ablative modality at most institutions. In the setting of patients of very early and early-stage hepatocellular carcinoma (HCC) – according to the Barcelona Clinic Liver Cancer (BCLC) staging system image-guided tumor ablation is recommended when patients are excluded from surgical options. The goal of RF ablation is to induce thermal injury to the tissue through electromagnetic energy deposition. One or multiple electrodes have to be inserted directly into the tumor to deliver RF energy current. Electrodes are coupled with RF generators and can be monopolar or bipolar, and they can have different designs (multitined expandable, internally cooled, perfused). Targeting of the lesion can be performed with US, CT, or MR imaging. The guidance system is chosen largely on the basis of operator preference and local availability of dedicated equipment such as fluoro-CT or open MR systems. RF ablation has shown superior anticancer effect and greater survival benefit with respect to the seminal percutaneous technique, ethanol injection, in meta-analyses of randomized controlled trials (RCTs), and is currently established as the standard method for local tumor treatment.


Thermal Ablation Barcelona Clinic Liver Cancer Complete Tumor Necrosis Heat Sink Effect Local Tumor Ablation 


  1. 1.
    Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329–38.CrossRefPubMedGoogle Scholar
  2. 2.
    Crocetti L, de Baere T, Lencioni R. Quality improvement guidelines for radiofrequency ablation of liver tumours. Cardiovasc Intervent Radiol. 2010;33:11–7.CrossRefPubMedGoogle Scholar
  3. 3.
    Orlando A, Leandro G, Olivo M, et al. Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials. Am J Gastroenterol. 2009;104:514–24.CrossRefPubMedGoogle Scholar
  4. 4.
    Cho YK, Kim JK, Kim MY, et al. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology. 2009;49:453–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Germani G, Pleguezuelo M, Gurusamy K, et al. Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta-analysis. J Hepatol. 2010;52:380–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology. 2010;52:762–73.CrossRefPubMedGoogle Scholar
  7. 7.
    Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–36.CrossRefPubMedGoogle Scholar
  8. 8.
    Lencioni R, Crocetti L, Pina MC, et al. Percutaneous image-guided radiofrequency ablation of liver tumors. Abdom Imaging. 2009;34:547–56.CrossRefPubMedGoogle Scholar
  9. 9.
    Lu DS, Yu NC, Raman SS, et al. Radiofrequency ablation of hepatocellular carcinoma: treatment success as defined by histologic examination of the explanted liver. Radiology. 2005;234:954–60.CrossRefPubMedGoogle Scholar
  10. 10.
    Rossi S, Garbagnati F, Lencioni R, et al. Percutaneous radio-frequency thermal ablation of nonresectable hepatocellular carcinoma after occlusion of tumor blood supply. Radiology. 2000;217:119–26.CrossRefPubMedGoogle Scholar
  11. 11.
    Lencioni R, Crocetti L, Petruzzi P, et al. Doxorubicin-eluting bead-enhanced radiofrequency ablation of hepatocellular carcinoma: a pilot clinical study. J Hepatol. 2008;49:217–22.CrossRefPubMedGoogle Scholar
  12. 12.
    Crocetti L, Della Pina C, Cioni D, et al. Peri-intraprocedural imaging: US, CT, and MRI. Abdom Imaging. 2011;36:648–60.CrossRefPubMedGoogle Scholar
  13. 13.
    Llovet JM, Di Bisceglie AM, Bruix J, et al. Panel of experts in HCC-design clinical trials. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100:698–711.CrossRefPubMedGoogle Scholar
  14. 14.
    Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52–60.CrossRefPubMedGoogle Scholar
  15. 15.
    Bruix J, Sherman M, Llovet JM, et al. EASL panel of experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. J Hepatol. 2001;35:421–30.CrossRefPubMedGoogle Scholar
  16. 16.
    Livraghi T, Solbiati L, Meloni MF, et al. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicentre study. Radiology. 2003;26:441–51.CrossRefGoogle Scholar
  17. 17.
    De Baere T, Risse O, Kuoch V, et al. Adverse events during radiofrequency treatment of 582 hepatic tumors. AJR Am J Roentgenol. 2003;181:695–700.CrossRefPubMedGoogle Scholar
  18. 18.
    Bleicher RJ, Allegra DP, Nora DT, et al. Radiofrequency ablation in 447 complex unresectable liver tumors: lessons learned. Ann Surg Oncol. 2003;10:52–8.CrossRefPubMedGoogle Scholar
  19. 19.
    Lencioni R, Cioni D, Crocetti L, et al. Early-stage hepatocellular carcinoma in cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology. 2005;234:961–7.CrossRefPubMedGoogle Scholar
  20. 20.
    Llovet JM, Vilana R, Bru C, et al. Barcelona clinic liver cancer (BCLC) group. Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology. 2001;33:1124–29.CrossRefPubMedGoogle Scholar
  21. 21.
    Lencioni R, Allgaier HP, Cioni D, et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radiofrequency thermal ablation versus percutaneous ethanol injection. Radiology. 2003;228:235–40.CrossRefPubMedGoogle Scholar
  22. 22.
    Lin SM, Lin CJ, Lin CC, et al. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm. Gastroenterology. 2004;127:1714–23.CrossRefPubMedGoogle Scholar
  23. 23.
    Shiina S, Teratani T, Obi S, et al. A randomized controlled trial of radiofrequency ablation versus ethanol injection for small hepatocellular carcinoma. Gastroenterology. 2005;129:122–30.CrossRefPubMedGoogle Scholar
  24. 24.
    Lin SM, Lin CJ, Lin CC, et al. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut. 2005;54:1151–6.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Brunello F, Veltri A, Carucci P, et al. Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: a randomized controlled trial. Scand J Gastroenterol. 2008;43:727–35.CrossRefPubMedGoogle Scholar
  26. 26.
    Tateishi R, Shiina S, Teratani T, et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma. Cancer. 2005;103:1201–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Cabassa P, Donato F, Simeone F, et al. Radiofrequency ablation of hepatocellular carcinoma: long-term experience with expandable needle electrodes. AJR Am J Roentgenol. 2006;185:S316–21.CrossRefGoogle Scholar
  28. 28.
    Choi D, Lim HK, Rhim H, et al. Percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma as a first- line treatment: long-term results and prognostic factors in a large single-institution series. Eur Radiol. 2007;17:684–92.CrossRefPubMedGoogle Scholar
  29. 29.
    Takahashi S, Kudo M, Chung H, et al. Initial treatment response is essential to improve survival in patients with hepatocellular carcinoma who underwent curative radiofrequency ablation therapy. Oncology. 2007;72:S98–103.CrossRefGoogle Scholar
  30. 30.
    Hiraoka A, Horiike N, Yamashita Y, et al. Efficacy of radiofrequency ablation therapy compared to surgical resection in 164 patients in Japan with single hepatocellular carcinoma smaller than 3 cm, along with report of complications. Hepatogastroenterology. 2008;55:2171–4.PubMedGoogle Scholar
  31. 31.
    N’Kontchou G, Mahamoudi A, Aout M, et al. Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis. Hepatology. 2009;50:1475–83.CrossRefPubMedGoogle Scholar
  32. 32.
    Chen MS, Li JQ, Zheng Y, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg. 2006;243:321–8.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Huang J, Yan L, Cheng Z, et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg. 2010;252:903–12.CrossRefPubMedGoogle Scholar
  34. 34.
    Yamasaki T, Kurokawa F, Shirahashi H, et al. Percutaneous radiofrequency ablation therapy for patients with hepatocellular carcinoma during occlusion of hepatic blood flow. Comparison with standard percutaneous radiofrequency ablation therapy. Cancer. 2002;95:2353–60.CrossRefPubMedGoogle Scholar
  35. 35.
    Veltri A, Moretto P, Doriguzzi A, et al. Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC). Eur Radiol. 2006;16:661–9.CrossRefPubMedGoogle Scholar
  36. 36.
    Helmberger T, Dogan S, Straub G, et al. Liver resection or combined chemoembolization and radiofrequency ablation improve survival in patients with hepatocellular carcinoma. Digestion. 2007;75:104–12.CrossRefPubMedGoogle Scholar
  37. 37.
  38. 38.
    Livraghi T, Meloni F, Di Stasi M, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology. 2008;47:82–9.CrossRefPubMedGoogle Scholar
  39. 39.
    Cho YK, Kim JK, Kim WT, et al. Hepatic resection versus radiofrequency ablation for very early stage hepatocellular carcinoma: a Markov model analysis. Hepatology. 2010;51:1284–90.CrossRefPubMedGoogle Scholar
  40. 40.
    Majno PE, Mentha G, Mazzaferro V. Partial hepatectomy versus radiofrequency ablation for hepatocellular carcinoma: confirming the trial that will never be, and some comments on the indications for liver resection. Hepatology. 2010;51:1116–8.CrossRefPubMedGoogle Scholar
  41. 41.
    Komorizono Y, Oketani M, Sako K, et al. Risk factors for local recurrence of small hepatocellular carcinoma tumors after a single session, single application of percutaneous radiofrequency ablation. Cancer. 2003;97:1253–62.CrossRefPubMedGoogle Scholar
  42. 42.
    Kim SW, Rhim H, Park M, et al. Percutaneous radiofrequency ablation of hepatocellular carcinomas adjacent to the gallbladder with internally cooled electrodes: assessment of safety and therapeutic efficacy. Korean J Radiol. 2009;10:366–76.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Teratani T, Yoshida H, Shiina S, et al. Radiofrequency ablation for hepatocellular carcinoma in so-called high-risk locations. Hepatology. 2006;43:1101–8.CrossRefPubMedGoogle Scholar
  44. 44.
    Lencioni R, Crocetti L. Local-regional treatment of hepatocellular carcinoma. Radiology. 2012;262:43–58.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Division of Diagnostic Imaging and Intervention, School of MedicineUniversity of Pisa, Cisanello HospitalPisaItaly

Personalised recommendations